Home NDC 68071-2421-7 Tadalafil
Product NDC 68071-2421
Requested package NDC 68071-2421-7
11-digit product format 680712421
Labeler code 68071
Product ID 68071-2421_59553b9e-5195-3bdb-e063-6394a90a93b6
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name Tadalafil
Dosage form TABLET
Route ORAL
Labeler NuCare Pharmaceuticals,Inc.
Application ANDA209654
Marketing category ANDA
Marketing start 2019-03-26
Substance TADALAFIL
Active strength 20 mg/1
Pharmacologic classes Phosphodiesterase 5 Inhibitor [EPC], Phosphodiesterase 5 Inhibitors [MoA]
NDC exclude flag No
Listing certified through 2027-12-31
Current FDA listing Yes Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 4 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date A209654-001 TADALAFIL TADALAFIL 2.5MG TABLET / ORAL AB1 2019-03-26 A209654-002 TADALAFIL TADALAFIL 5MG TABLET / ORAL AB1 2019-03-26 A209654-003 TADALAFIL TADALAFIL 10MG TABLET / ORAL AB1 2019-03-26 A209654-004 TADALAFIL TADALAFIL 20MG TABLET / ORAL AB1 2019-03-26
Therapeutic equivalence codes# Current TE-code rows page 1 of 1 · 4 matching rows.
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 1 of 5 · 180 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-11-14 07:37:17 2026-10 A209654-001 TADALAFIL 2.5MG TABLET / ORAL AB1 2019-03-26 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 A209654-002 TADALAFIL 5MG TABLET / ORAL AB1 2019-03-26 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 A209654-003 TADALAFIL 10MG TABLET / ORAL AB1 2019-03-26 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 A209654-004 TADALAFIL 20MG TABLET / ORAL AB1 2019-03-26 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 A209654-001 TADALAFIL 2.5MG TABLET / ORAL AB1 2019-03-26 c2088c7a36db…2026-10-15 13:18:30 2026-09 A209654-002 TADALAFIL 5MG TABLET / ORAL AB1 2019-03-26 c2088c7a36db…2026-10-15 13:18:30 2026-09 A209654-003 TADALAFIL 10MG TABLET / ORAL AB1 2019-03-26 c2088c7a36db…2026-10-15 13:18:30 2026-09 A209654-004 TADALAFIL 20MG TABLET / ORAL AB1 2019-03-26 c2088c7a36db…2026-09-14 22:38:34 2026-08 A209654-001 TADALAFIL 2.5MG TABLET / ORAL AB1 2019-03-26 84e616aacf4f…2026-09-14 22:38:34 2026-08 A209654-002 TADALAFIL 5MG TABLET / ORAL AB1 2019-03-26 84e616aacf4f…2026-09-14 22:38:34 2026-08 A209654-003 TADALAFIL 10MG TABLET / ORAL AB1 2019-03-26 84e616aacf4f…2026-09-14 22:38:34 2026-08 A209654-004 TADALAFIL 20MG TABLET / ORAL AB1 2019-03-26 84e616aacf4f…2026-08-18 06:07:40 2026-07 A209654-001 TADALAFIL 2.5MG TABLET / ORAL AB1 2019-03-26 caaa826d4ba7…2026-08-18 06:07:40 2026-07 A209654-002 TADALAFIL 5MG TABLET / ORAL AB1 2019-03-26 caaa826d4ba7…2026-08-18 06:07:40 2026-07 A209654-003 TADALAFIL 10MG TABLET / ORAL AB1 2019-03-26 caaa826d4ba7…2026-08-18 06:07:40 2026-07 A209654-004 TADALAFIL 20MG TABLET / ORAL AB1 2019-03-26 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 A209654-001 TADALAFIL 2.5MG TABLET / ORAL AB1 2019-03-26 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 A209654-002 TADALAFIL 5MG TABLET / ORAL AB1 2019-03-26 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 A209654-003 TADALAFIL 10MG TABLET / ORAL AB1 2019-03-26 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 A209654-004 TADALAFIL 20MG TABLET / ORAL AB1 2019-03-26 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 A209654-001 TADALAFIL 2.5MG TABLET / ORAL AB1 2019-03-26 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 A209654-002 TADALAFIL 5MG TABLET / ORAL AB1 2019-03-26 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 A209654-003 TADALAFIL 10MG TABLET / ORAL AB1 2019-03-26 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 A209654-004 TADALAFIL 20MG TABLET / ORAL AB1 2019-03-26 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 A209654-001 TADALAFIL 2.5MG TABLET / ORAL AB1 2019-03-26 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 A209654-002 TADALAFIL 5MG TABLET / ORAL AB1 2019-03-26 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 A209654-003 TADALAFIL 10MG TABLET / ORAL AB1 2019-03-26 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 A209654-004 TADALAFIL 20MG TABLET / ORAL AB1 2019-03-26 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 A209654-001 TADALAFIL 2.5MG TABLET / ORAL AB1 2019-03-26 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 A209654-002 TADALAFIL 5MG TABLET / ORAL AB1 2019-03-26 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 A209654-003 TADALAFIL 10MG TABLET / ORAL AB1 2019-03-26 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 A209654-004 TADALAFIL 20MG TABLET / ORAL AB1 2019-03-26 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 A209654-001 TADALAFIL 2.5MG TABLET / ORAL AB1 2019-03-26 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 A209654-002 TADALAFIL 5MG TABLET / ORAL AB1 2019-03-26 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 A209654-003 TADALAFIL 10MG TABLET / ORAL AB1 2019-03-26 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 A209654-004 TADALAFIL 20MG TABLET / ORAL AB1 2019-03-26 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 A209654-001 TADALAFIL 2.5MG TABLET / ORAL AB1 2019-03-26 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 A209654-002 TADALAFIL 5MG TABLET / ORAL AB1 2019-03-26 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 A209654-003 TADALAFIL 10MG TABLET / ORAL AB1 2019-03-26 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 A209654-004 TADALAFIL 20MG TABLET / ORAL AB1 2019-03-26 03ed91905a0d…
Observed Orange Book normalized TE history# Normalized TE history page 1 of 5 · 180 observed states.
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
Finished product Yes
Brand name base Tadalafil
Listing expiration 2027-12-31 Active Ingredients# Ingredient, Strength table Ingredient Strength TADALAFIL 20 mg/1
Harmonized UNII identifiers# UNII identifiers page 1 of 1 · 1 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 742SXX0ICT Internal UNII lookup
Harmonized RxCUI identifiers# RxCUI identifiers page 1 of 1 · 1 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 402019 Internal RxNorm lookup
Harmonized SPL set identifiers# SPL set identifiers page 1 of 1 · 1 matching rows.
DailyMed Product Concepts# FDA-Initiated Inactive NDC Indexing# NDC, Related label table NDC Related label 68071-2421-1 These highlights do not include all the information needed to use TADALAFIL TABLETS safely and effectively. See full prescribing information for TADALAFIL TABLETS. TADALAFIL tablets, for oral use Initial U.S. Approval: 2003 68071-2421-1 These highlights do not include all the information needed to use TADALAFIL TABLETS safely and effectively. See full prescribing information for TADALAFIL TABLETS. TADALAFIL tablets, for oral use Initial U.S. Approval: 2003 68071-2421-1 These highlights do not include all the information needed to use TADALAFIL TABLETS safely and effectively. See full prescribing information for TADALAFIL TABLETS. TADALAFIL tablets, for oral use Initial U.S. Approval: 2003 68071-2421-4 These highlights do not include all the information needed to use TADALAFIL TABLETS safely and effectively. See full prescribing information for TADALAFIL TABLETS. TADALAFIL tablets, for oral use Initial U.S. Approval: 2003 68071-2421-4 These highlights do not include all the information needed to use TADALAFIL TABLETS safely and effectively. See full prescribing information for TADALAFIL TABLETS. TADALAFIL tablets, for oral use Initial U.S. Approval: 2003 68071-2421-4 These highlights do not include all the information needed to use TADALAFIL TABLETS safely and effectively. See full prescribing information for TADALAFIL TABLETS. TADALAFIL tablets, for oral use Initial U.S. Approval: 2003 68071-2421-5 These highlights do not include all the information needed to use TADALAFIL TABLETS safely and effectively. See full prescribing information for TADALAFIL TABLETS. TADALAFIL tablets, for oral use Initial U.S. Approval: 2003 68071-2421-5 These highlights do not include all the information needed to use TADALAFIL TABLETS safely and effectively. See full prescribing information for TADALAFIL TABLETS. TADALAFIL tablets, for oral use Initial U.S. Approval: 2003 68071-2421-5 These highlights do not include all the information needed to use TADALAFIL TABLETS safely and effectively. See full prescribing information for TADALAFIL TABLETS. TADALAFIL tablets, for oral use Initial U.S. Approval: 2003 68071-2421-6 These highlights do not include all the information needed to use TADALAFIL TABLETS safely and effectively. See full prescribing information for TADALAFIL TABLETS. TADALAFIL tablets, for oral use Initial U.S. Approval: 2003 68071-2421-6 These highlights do not include all the information needed to use TADALAFIL TABLETS safely and effectively. See full prescribing information for TADALAFIL TABLETS. TADALAFIL tablets, for oral use Initial U.S. Approval: 2003 68071-2421-6 These highlights do not include all the information needed to use TADALAFIL TABLETS safely and effectively. See full prescribing information for TADALAFIL TABLETS. TADALAFIL tablets, for oral use Initial U.S. Approval: 2003
DailyMed Package Descriptions# Package NDC, Product, Description table Package NDC Product Description Form Quantity Strength SPL version 68071-2421-1 Tadalafil 10 in 1 BOTTLE TABLET 10 4 68071-2421-4 Tadalafil 24 in 1 BOTTLE TABLET 24 4 68071-2421-5 Tadalafil 5 in 1 BOTTLE TABLET 5 4 68071-2421-6 Tadalafil 60 in 1 BOTTLE TABLET 60 4
DailyMed Dashboard NDC Coverage# NDC, Dashboard title, SPL version table NDC Dashboard title SPL version Validation Dashboard ZIP 68071-2421 TADALAFIL TABLET [NUCARE PHARMACEUTICALS,INC.] 4 Current NDC, Legacy NDC, 4 package rows 20221027_c3409762-3b2b-1cfc-e053-2995a90ab91b.zip
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 2 of 2 · 22 matching rows.
DailyMed RxNorm Mappings# Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Units Marketing start Sample Exclude flag Status 68071-2421-7 68071242107 5 TABLET in 1 BOTTLE (68071-2421-7) 5 tablet 2021-05-26 No No Current